TapewireFind a company

person · Reporting owner

Vasisht Niraj

Disclosed activity across 2 companies

Tapewire entity
42896
SEC CIK
0001662930

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIODELIVERY SCIENCES INTERNATIONAL INCBDSI · Entity 128876SVP & Chief Technology OfficerMarch 24, 2017March 24, 2017
Inhibitor Therapeutics, Inc.INTI · Entity 7783DirectorMay 05, 2026June 01, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIODELIVERY SCIENCES INTERNATIONAL INC

Report date March 24, 2017 · Filed March 24, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect272,413 Ending reported balance After 2017-03-23 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2017-03-22 · Grant · Acquired 1,474 · Balance 272,943

F1: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan.

Row 2 · 2017-03-23 · Sale · Disposed 530 · Balance 272,413

F2: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-03-22Direct0 Reported balance After 2017-03-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2017-03-22 · Grant · Acquired 1,474 · Balance 0

F1: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan.

F2: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.

Inhibitor Therapeutics, Inc.

Report date May 05, 2026 · Filed June 01, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect200,000 Reported balance After 2026-05-05 transaction · row 1
1 source row

Row 1 · 2026-05-05 · Grant · Acquired 50,000 · Balance 200,000

F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 05, 2026 Filed Jun 1, 2026 20:15 UTC Inhibitor Therapeutics, Inc. INTI · Entity 7783 GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001493152-26-026623 · ownership.xml · nonDerivative · entry 1

Vasisht Niraj · CIK 0001662930 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.

Read SEC document
April 01, 2025 Filed Apr 10, 2025 17:30 UTC Inhibitor Therapeutics, Inc. INTI · Entity 7783 GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001641172-25-003556 · ownership.xml · nonDerivative · entry 1

Vasisht Niraj · CIK 0001662930 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

Read SEC document
March 23, 2017 Filed Mar 24, 2017 18:07 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 530 $1.90 $1,007.00
Disclosure

SEC source: 0000899243-17-008553 · doc4.xml · nonDerivative · entry 2

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,413

F2 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.

Read SEC document
March 22, 2017 Filed Mar 24, 2017 18:07 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantRestricted Stock Units · Derivative 1,474 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-17-008553 · doc4.xml · derivative · entry 3

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,474 shares

Expires 2017-03-22

F1 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan.

Read SEC document
March 22, 2017 Filed Mar 24, 2017 18:07 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantCommon Stock 1,474 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-008553 · doc4.xml · nonDerivative · entry 1

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,943

F1 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan.

Read SEC document
March 01, 2017 Filed Mar 3, 2017 19:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 50,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-17-006500 · doc4.xml · derivative · entry 9

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 50,000 shares

Expires 2019-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019.

Read SEC document
March 01, 2017 Filed Mar 3, 2017 19:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 9,000 $2.03 $18,270.00
Disclosure

SEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 6

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,469

F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs.

F7 · price: On March 1, 2017, the Reporting Person sold an aggregate of 9,000 shares of the Issuer's Common Stock at a weighted average price of $2.03 per share. The highest sale price for the Common Stock was $2.05 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 01, 2017 Filed Mar 3, 2017 19:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 5

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019.

F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019.

Read SEC document
February 23, 2017 Filed Mar 3, 2017 19:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 66,667 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-17-006500 · doc4.xml · derivative · entry 8

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,666

Underlying: Common Stock · 66,667 shares

Expires 2018-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018.

Read SEC document
February 23, 2017 Filed Mar 3, 2017 19:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 23,500 $1.95 $45,825.00
Disclosure

SEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 4

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,469

F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs.

F5 · price: On February 23, 2017, the Reporting Person sold an aggregate of 23,500 shares of the Issuer's Common Stock at a weighted average price of $1.95 per share. The highest sale price for the Common Stock was $2.05 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 23, 2017 Filed Mar 3, 2017 19:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 66,667 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 3

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,969

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018.

F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018.

Read SEC document
February 22, 2017 Filed Mar 3, 2017 19:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 24,980 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-17-006500 · doc4.xml · derivative · entry 7

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,980 shares

Expires 2017-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan").

Read SEC document
February 22, 2017 Filed Mar 3, 2017 19:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 9,500 $2.01 $19,095.00
Disclosure

SEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 2

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,302

F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs.

F3 · price: On February 22, 2017, the Reporting Person sold an aggregate of 9,500 shares of the Issuer's Common Stock at a weighted average price of $2.01 per share. The highest sale price for the Common Stock was $2.06 per share and the lowest sale price was $1.96 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 22, 2017 Filed Mar 3, 2017 19:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 24,980 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 1

Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,802

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan").

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan").

Read SEC document
February 06, 2017 Filed Feb 8, 2017 18:00 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantRestricted Stock Units · Derivative 162,500 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-17-003152 · doc4.xml · derivative · entry 4

Vasisht Niraj · CIK 0001662930 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,500

Underlying: Common Stock · 162,500 shares

Expires 2020-03-18

F4 · kind: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders.

F4 · derivative.exercise_date: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders.

Read SEC document
January 30, 2017 Filed Feb 8, 2017 18:00 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 16,666 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-17-003152 · doc4.xml · derivative · entry 3

Vasisht Niraj · CIK 0001662930 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,666 shares

Expires 2017-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on January 30, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan").

Read SEC document
January 30, 2017 Filed Feb 8, 2017 18:00 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 6,905 $1.91 $13,188.55
Disclosure

SEC source: 0000899243-17-003152 · doc4.xml · nonDerivative · entry 2

Vasisht Niraj · CIK 0001662930 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,822

F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs.

F3 · price: On January 30, 2017, the Reporting Person sold an aggregate of 6,905 shares of the Issuer's Common Stock at a weighted average price of $1.91 per share. The highest sale price for the Common Stock was $1.95 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 30, 2017 Filed Feb 8, 2017 18:00 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 16,666 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-003152 · doc4.xml · nonDerivative · entry 1

Vasisht Niraj · CIK 0001662930 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on January 30, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan").

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on January 30, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan").

Read SEC document
September 23, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 7,000 $2.68 $18,760.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 7

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,061

F8 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of RSUs.

F9 · price: On September 23, 2016, the Reporting Person sold an aggregate of 7,000 shares of the Issuer's Common Stock at a weighted average price of $2.68 per share. The highest sale price for the Common Stock was $2.81 per share and the lowest sale price was $2.58 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 66,667 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · derivative · entry 11

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,333

Underlying: Common Stock · 66,667 shares

Expires 2018-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 24,980 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · derivative · entry 10

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,980

Underlying: Common Stock · 24,980 shares

Expires 2017-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 16,667 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · derivative · entry 9

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,666

Underlying: Common Stock · 16,667 shares

Expires 2017-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on January 30, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on January 30, 2017.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 27,666 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · derivative · entry 8

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,666 shares

Expires 2016-09-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 27,666 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 40,000 $2.39 $95,600.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 6

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,061

F6 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.

F7 · price: On September 21, 2016, the Reporting Person sold an aggregate of 40,000 shares of the Issuer's Common Stock at a weighted average price of $2.39 per share. The highest sale price for the Common Stock was $2.45 per share and the lowest sale price was $2.35 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 66,667 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 5

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018.

F5 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 24,980 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 4

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,394

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017.

F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 16,667 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 3

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on January 30, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on January 30, 2017.

F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on January 30, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on January 30, 2017.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 27,666 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 2

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,747

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 27,666 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016.

F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 27,666 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016.

Read SEC document
September 21, 2016 Filed Sep 23, 2016 18:30 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantCommon Stock 4,661 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 1

Vasisht Niraj · CIK 0001662930 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,081

F1 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.